GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyteir Therapeutics Inc (OTCPK:CYTT) » Definitions » Volatility

Cyteir Therapeutics (Cyteir Therapeutics) Volatility : 14.62% (As of May. 03, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Cyteir Therapeutics Volatility?

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2024-05-03), Cyteir Therapeutics's Volatility is 14.62%.


Competitive Comparison of Cyteir Therapeutics's Volatility

For the Biotechnology subindustry, Cyteir Therapeutics's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyteir Therapeutics's Volatility Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cyteir Therapeutics's Volatility distribution charts can be found below:

* The bar in red indicates where Cyteir Therapeutics's Volatility falls into.



Cyteir Therapeutics  (OTCPK:CYTT) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * 12
= 1/(n-1) ∑(Ri - R')^2 * 12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cyteir Therapeutics  (OTCPK:CYTT) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.


Cyteir Therapeutics Volatility Related Terms

Thank you for viewing the detailed overview of Cyteir Therapeutics's Volatility provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyteir Therapeutics (Cyteir Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
128 Spring Street, Building A, Suite 510, Lexington, MA, USA, 02421
Cyteir Therapeutics Inc is a clinical-stage biotechnology company focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor or MCT inhibitor, initially evaluated in a phase 1/2 study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard-of-care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy.
Executives
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Joseph S Zakrzewski director 509 WATERVIEW PLACE, NEW HOPE PA 18938
John F Thero director C/O AMARIN PHARMA, INC., 1430 ROUTE 6, BEDMINSTER NJ 07921
Adam M Veness officer: General Counsel C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Stephen H. Sands director 128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421
Jeffrey Humphrey director C/O CONSTELLATION PHARMACEUTICALS, INC., 215 FIRST STREET, SUITE 200, CAMBRIDGE MA 02142
Droia Invest Ii Scsp 10 percent owner 28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Janwillem Naesens director 128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421
Sa Ihl 10 percent owner 28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Karen Hong director 69 PARKSIDE DRIVE, PRINCETON NJ 08540
Bv Wepaven 10 percent owner BRUSSELSESTEENWEG 11, MEISE C9 1860
Luc Verelst 10 percent owner 28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Df Ii Gp Sarl 10 percent owner 28 BOULEVARD JOSEPH II, LUXEMBOURG N4 L-1840
Timothy Romberger director 128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421
Racquel Bracken director 128 SPRING STREET, BUILDING A, SUITE 510, LEXINGTON MA 02421

Cyteir Therapeutics (Cyteir Therapeutics) Headlines

From GuruFocus

Cyteir Therapeutics Promotes David Gaiero to Chief Financial Officer

By Business Wire Business Wire 02-06-2023